Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 100

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

The role of p53 in anti-tumor immunity and response to immunotherapy

Carlsen, Lindsey, Zhang, Shengliang, Tian, Xiaobing, De La Cruz, Arielle, George, Andrew, Arnoff, Taylor E., El-Deiry, Wafik S.·2023·Frontiers in Molecular Biosciences
DOI 10.3389/fmolb.2023.1148389
Open this paper in CoChat — free account

Abstract

p53 is a transcription factor that regulates the expression of genes involved in tumor suppression. p53 mutations mediate tumorigenesis and occur in approximately 50% of human cancers. p53 regulates hundreds of target genes that induce various cell fates including apoptosis, cell cycle arrest, and DNA damage repair. p53 also plays an important role in anti-tumor immunity by regulating TRAIL, DR5, TLRs, Fas, PKR, ULBP1/2, and CCL2; T-cell inhibitory ligand PD-L1; pro-inflammatory cytokines; immune cell activation state; and antigen presentation. Genetic alteration of p53 can contribute to immune evasion by influencing immune cell recruitment to the tumor, cytokine secretion in the TME, and inflammatory signaling pathways. In some contexts, p53 mutations increase neoantigen load which improves response to immune checkpoint inhibition. Therapeutic restoration of mutated p53 can restore anti-cancer immune cell infiltration and ameliorate pro-tumor signaling to induce tumor regression. Indeed, there is clinical evidence to suggest that restoring p53 can induce an anti-cancer immune response in immunologically cold tumors. Clinical trials investigating the combination of p53-restoring compounds or p53-based vaccines with immunotherapy have demonstrated anti-tumor immune activation and tumor regression with heterogeneity across cancer type. In this Review, we discuss the impact of wild-type and mutant p53 on the anti-tumor immune response, outline clinical progress as far as activating p53 to induce an immune response across a variety of cancer types, and highlight open questions limiting effective clinical translation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fmolb.2023.1148389

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Research works printed but not linked: 117

  1. Adorno, 2009, A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis, Cell, 137, 87, 10.1016/j.cell.2009.01.039 · DOI · Paper page
  2. Agupitan, 2020, P53: A guardian of immunity becomes its saboteur through mutation, Int. J. Mol. Sci., 21, 3452, 10.3390/ijms21103452 · DOI
  3. Alvarez, 2019, TGF-β inhibitors in metastatic pancreatic ductal adenocarcinoma, J. Gastrointest. Cancer, 50, 207, 10.1007/s12029-018-00195-5 · DOI
  4. Banerjee, 2016, Lack of p53 augments antitumor functions in cytolytic T cells, Cancer Res., 76, 5229, 10.1158/0008-5472.Can-15-1798 · DOI
  5. Barnes, 2003, Interferon regulatory factor 5, a novel mediator of cell cycle arrest and cell death, Cancer Res., 63, 6424
  6. Bezzi, 2018, Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms, Nat. Med., 24, 165, 10.1038/nm.4463 · DOI · Paper page
  7. Biton, 2018, TP53, STK11, and EGFR mutations predict tumor immune profile and the response to anti-PD-1 in lung adenocarcinoma, Clin. Cancer Res., 24, 5710, 10.1158/1078-0432.Ccr-18-0163 · DOI · Paper page
  8. Blagih, Cancer-specific loss of p53 leads to a modulation of myeloid and T cell responses, Cell Rep., 30, 481, 10.1016/j.celrep.2019.12.028 · DOI · Paper page
  9. Braun, 2016, Regulation of cytotoxic T-cell responses by p53 in cancer, Transl. Cancer Res., 5, 692, 10.21037/tcr.2016.11.76 · DOI
  10. Burns, 2001, Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53-dependent apoptosis in vivo, Oncogene, 20, 4601, 10.1038/sj.onc.1204484 · DOI
  11. Camphausen, 2003, Radiation abscopal antitumor effect is mediated through p53, Cancer Res., 63, 1990
  12. Cardoso Alves, 2021, The multifaceted role of TRAIL signaling in cancer and immunity, Febs J., 288, 5530, 10.1111/febs.15637 · DOI
  13. Carlsen, 2021, Pan-drug and drug-specific mechanisms of 5-FU, irinotecan (CPT-11), oxaliplatin, and cisplatin identified by comparison of transcriptomic and cytokine responses of colorectal cancer cells, Oncotarget, 12, 2006, 10.18632/oncotarget.28075 · DOI
  14. Chakraborty, 2004, External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing, Cancer Res., 64, 4328, 10.1158/0008-5472.Can-04-0073 · DOI · Paper page
  15. Chasov, 2021, Promising new tools for targeting p53 mutant cancers: Humoral and cell-based immunotherapies, Front. Immunol., 12, 707734, 10.3389/fimmu.2021.707734 · DOI
  16. Choi, 2014, NFκB and STAT3 synergistically activate the expression of FAT10, a gene counteracting the tumor suppressor p53, Mol. Oncol., 8, 642, 10.1016/j.molonc.2014.01.007 · DOI
  17. Chung, 2021, Tgf-β signaling: From tissue fibrosis to tumor microenvironment, Int. J. Mol. Sci., 22, 7575, 10.3390/ijms22147575 · DOI · Paper page
  18. Chung, 2019, Evaluation of safety and efficacy of p53MVA vaccine combined with pembrolizumab in patients with advanced solid cancers, Clin. Transl. Oncol., 21, 363, 10.1007/s12094-018-1932-2 · DOI
  19. Chung, 2013, A phase I study of an MVA vaccine targeting p53 in cancer, J. Clin. Oncol., 31, 3089, 10.1200/jco.2013.31.15_suppl.3089 · DOI
  20. Cooks, 2013, Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer, Cancer Cell, 23, 634, 10.1016/j.ccr.2013.03.022 · DOI · Paper page
  21. Cooks, 2018, Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246, Nat. Commun., 9, 771, 10.1038/s41467-018-03224-w · DOI · Paper page
  22. Costa, 2020, P53-regulated miR-320a targets PDL1 and is downregulated in malignant mesothelioma, Cell Death Dis., 11, 748, 10.1038/s41419-020-02940-w · DOI
  23. Couzinet, 2008, A cell-type-specific requirement for IFN regulatory factor 5 (IRF5) in Fas-induced apoptosis, Proc. Natl. Acad. Sci. U. S. A., 105, 2556, 10.1073/pnas.0712295105 · DOI
  24. Cui, 2016, Immunomodulatory function of the tumor suppressor p53 in host immune response and the tumor microenvironment, Int. J. Mol. Sci., 17, 1942, 10.3390/ijms17111942 · DOI
  25. Decout, 2021, The cGAS-STING pathway as a therapeutic target in inflammatory diseases, Nat. Rev. Immunol., 21, 548, 10.1038/s41577-021-00524-z · DOI · Paper page
  26. DeLeo, 1979, Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse, Proc. Natl. Acad. Sci. U. S. A., 76, 2420, 10.1073/pnas.76.5.2420 · DOI · Paper page
  27. Deniger, 2018, T-Cell responses to TP53 "hotspot" mutations and unique neoantigens expressed by human ovarian cancers, Clin. Cancer Res., 24, 5562, 10.1158/1078-0432.Ccr-18-0573 · DOI
  28. Di Minin, 2014, Mutant p53 reprograms TNF signaling in cancer cells through interaction with the tumor suppressor DAB2IP, Mol. Cell, 56, 617, 10.1016/j.molcel.2014.10.013 · DOI · Paper page
  29. Dosset, 2018, PD-1/PD-L1 pathway: An adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer, Oncoimmunology, 7, e1433981, 10.1080/2162402x.2018.1433981 · DOI · Paper page
  30. Du, 2021, cGAS-STING signaling in cancer immunity and immunotherapy, Biomed. Pharmacother., 133, 110972, 10.1016/j.biopha.2020.110972 · DOI
  31. Dubuisson, 2017, Antibodies and derivatives targeting DR4 and DR5 for cancer therapy, Antibodies (Basel), 6, 16, 10.3390/antib6040016 · DOI
  32. Dujka, 2010, ATM and p53 are essential in the cell-cycle containment of DNA breaks during V(D)J recombination in vivo, Oncogene, 29, 957, 10.1038/onc.2009.394 · DOI
  33. Dumbrava, 2021, Phase 1/2 study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with solid tumor malignancies, J. Clin. Oncol., 39, TPS3161, 10.1200/JCO.2021.39.15_suppl.TPS3161 · doi:10.1200/jco.2021.39.15_suppl.tps3161
  34. el-Deiry, 1994, WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis, Cancer Res., 54, 1169
  35. El-Deiry, 1993, WAF1, a potential mediator of p53 tumor suppression, Cell, 75, 817, 10.1016/0092-8674(93)90500-p · DOI · Paper page
  36. Elston, 2012, Crosstalk between p53 and TGF-β signalling, J. signal Transduct., 2012, 294097, 10.1155/2012/294097 · DOI
  37. Falschlehner, 2009, Following TRAIL's path in the immune system, Immunology, 127, 145, 10.1111/j.1365-2567.2009.03058.x · DOI · Paper page
  38. Fei, 2021, Targeting the CCL2/CCR2 Axis in cancer immunotherapy: One stone, three birds?, Front. Immunol., 12, 771210, 10.3389/fimmu.2021.771210 · DOI · Paper page
  39. Fei, 2002, Tissue-specific induction of p53 targets in vivo, Cancer Res., 62, 7316
  40. Formenti, 2012, Radiation therapy to convert the tumor into an in situ vaccine, Int. J. Radiat. Oncol. Biol. Phys., 84, 879, 10.1016/j.ijrobp.2012.06.020 · DOI · Paper page
  41. Gans, 2021, Administration of TGF-ß inhibitor mitigates radiation-induced fibrosis in a mouse model, Clin. Orthop. Relat. Res., 479, 468, 10.1097/CORR.0000000000001286 · DOI
  42. Ghosh, 2021, Mutant p53 suppresses innate immune signaling to promote tumorigenesis, Cancer Cell, 39, 494, 10.1016/j.ccell.2021.01.003 · DOI · Paper page
  43. Groysman, 2021, Chemotherapy-induced cytokines and prognostic gene signatures vary across breast and colorectal cancer, Am. J. Cancer Res., 11, 6086
  44. Gudkov, 2011, Inflammation and p53: A tale of two stresses, Genes Cancer, 2, 503, 10.1177/1947601911409747 · DOI · Paper page
  45. Han, 2020, PD-1/PD-L1 pathway: Current researches in cancer, Am. J. Cancer Res., 10, 727
  46. Hayashi, 2019, Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia, Nat. Commun., 10, 4869, 10.1038/s41467-019-12555-1 · DOI
  47. Hofmann, 2009, Identification and characterization of survivin-derived H-2Kb-restricted CTL epitopes, Eur. J. Immunol., 39, 1419, 10.1002/eji.200839098 · doi:10.1002/eji.200839098
  48. Hoffman, 2002, Transcriptional repression of the anti-apoptotic survivin gene by wild type p53, J. Biol. Chem., 277, 3247, 10.1074/jbc.M106643200 · DOI · Paper page
  49. Honda, 2006, IRFs: Master regulators of signalling by toll-like receptors and cytosolic pattern-recognition receptors, Nat. Rev. Immunol., 6, 644, 10.1038/nri1900 · DOI · Paper page
  50. Hu, 2009, IRF-5 is a mediator of the death receptor-induced apoptotic signaling pathway, J. Biol. Chem., 284, 2767, 10.1074/jbc.M804744200 · DOI
  51. Hu, 2005, Signaling through IFN regulatory factor-5 sensitizes p53-deficient tumors to DNA damage-induced apoptosis and cell death, Cancer Res., 65, 7403, 10.1158/0008-5472.Can-05-0583 · DOI
  52. Iannello, 2013, p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells, J. Exp. Med., 210, 2057, 10.1084/jem.20130783 · DOI · Paper page
  53. Jacob, 2021, Clinical characteristics and outcomes of oral mucositis associated with immune checkpoint inhibitors in patients with cancer, J. Natl. Compr. Canc Netw., 19, 1415, 10.6004/jnccn.2020.7697 · DOI
  54. Jiang, 2018, Immunogenomics analysis reveals that TP53 mutations inhibit tumor immunity in gastric cancer, Transl. Oncol., 11, 1171, 10.1016/j.tranon.2018.07.012 · DOI · Paper page
  55. Ju, 2019, Mutant p53 increases exosome-mediated transfer of miR-21-3p and miR-769-3p to promote pulmonary metastasis, Chin. J. Cancer Res., 31, 533, 10.21147/j.issn.1000-9604.2019.03.15 · DOI
  56. Kalo, 2007, Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II, Mol. Cell. Biol., 27, 8228, 10.1128/MCB.00374-07 · DOI
  57. Ke, 2022, cGAS-STING signaling pathway in gastrointestinal inflammatory disease and cancers, FASEB J., 36, e22029, 10.1096/fj.202101199R · DOI
  58. Kerkar, 2012, Cellular constituents of immune escape within the tumor microenvironment, Cancer Res., 72, 3125, 10.1158/0008-5472.CAN-11-4094 · DOI · Paper page
  59. Krześniak, 2020, Synergistic activation of p53 by actinomycin D and nutlin-3a is associated with the upregulation of crucial regulators and effectors of innate immunity, Cell Signal, 69, 109552, 10.1016/j.cellsig.2020.109552 · DOI
  60. Kuribayashi, 2008, TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death, Cancer Biol. Ther., 7, 2034, 10.4161/cbt.7.12.7460 · DOI
  61. Lalle, 2021, NF-κB in cancer immunity: Friend or foe?, Cells, 10, 355, 10.3390/cells10020355 · DOI
  62. Li, 2011, Pharmacological activation of p53 triggers anticancer innate immune response through induction of ULBP2, Cell Cycle, 10, 3346, 10.4161/cc.10.19.17630 · DOI
  63. Liu, 2018, Abscopal effect of radiotherapy combined with immune checkpoint inhibitors, J. Hematol. Oncol., 11, 104, 10.1186/s13045-018-0647-8 · DOI · Paper page
  64. Lopes-Paciencia, 2019, The senescence-associated secretory phenotype and its regulation, Cytokine, 117, 15, 10.1016/j.cyto.2019.01.013 · DOI · Paper page
  65. Lu, 2012, Novel role of PKR in inflammasome activation and HMGB1 release, Nature, 488, 670, 10.1038/nature11290 · DOI · Paper page
  66. Lyu, 2019, Correlate the TP53 mutation and the HRAS mutation with immune signatures in head and neck squamous cell cancer, Comput. Struct. Biotechnol. J., 17, 1020, 10.1016/j.csbj.2019.07.009 · DOI · Paper page
  67. Martinez, 2010, Restoring p53 tumor suppressor activity as an anticancer therapeutic strategy, Future Oncol., 6, 1857, 10.2217/fon.10.132 · DOI
  68. McCarty, 1998, Targeting p53 for adoptive T-cell immunotherapy, Cancer Res., 58, 2601
  69. McKean, 2022, Newly updated activity results of alrizomadlin (APG-115), a novel MDM2/p53 inhibitor, plus pembrolizumab: Phase 2 study in adults and children with various solid tumors, J. Clin. Oncol., 40, 9517, 10.1200/JCO.2022.40.16_suppl.9517 · DOI
  70. Menendez, 2013, Interactions between the tumor suppressor p53 and immune responses, Curr. Opin. Oncol., 25, 85, 10.1097/CCO.0b013e32835b6386 · DOI
  71. Meric-Bernstam, 2017, Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas, J. Clin. Oncol., 35, 2505, 10.1200/JCO.2017.35.15_suppl.2505 · DOI · Paper page
  72. Meyer, 2017, Tissue TGF-β expression following conventional radiotherapy and pulsed low-dose-rate radiation, Cell Cycle, 16, 1171, 10.1080/15384101.2017.1317418 · doi:10.1080/15384101.2017.1317418
  73. Mori, 2002, Identification of the interferon regulatory factor 5 gene (IRF-5) as a direct target for p53, Oncogene, 21, 2914, 10.1038/sj.onc.1205459 · DOI · Paper page
  74. Muñoz-Fontela, 2008, Transcriptional role of p53 in interferon-mediated antiviral immunity, J. Exp. Med., 205, 1929, 10.1084/jem.20080383 · DOI · Paper page
  75. Muresan, 2020, Toll-like receptor 3 in solid cancer and therapy resistance, Cancers (Basel), 12, 3227, 10.3390/cancers12113227 · DOI
  76. Nan, 2018, IRF9 and unphosphorylated STAT2 cooperate with NF-κB to drive IL6 expression, Proc. Natl. Acad. Sci. U. S. A., 115, 3906, 10.1073/pnas.1714102115 · DOI
  77. Niu, 2005, Role of Stat3 in regulating p53 expression and function, Mol. Cell Biol., 25, 7432, 10.1128/MCB.25.17.7432-7440.2005 · DOI · Paper page
  78. Okan Cakir, 2019, Hyperprogression after immunotherapy: A comprehensive review, J. buon, 24, 2232
  79. Park, 2022, Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors, ESMO Open, 7, 100573, 10.1016/j.esmoop.2022.100573 · DOI
  80. Petroni, 2022, Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer, Nat. Rev. Clin. Oncol., 19, 114, 10.1038/s41571-021-00579-w · DOI · Paper page
  81. Pu, 2021, Immune regulation of the cGAS-STING signaling pathway in the tumor microenvironment and its clinical application, Onco Targets Ther., 14, 1501, 10.2147/ott.S298958 · DOI
  82. Rahman, 2009, PKR is not a universal target of tumor suppressor p53 in response to genotoxic stress, Cell Cycle, 8, 3606, 10.4161/cc.8.21.9848 · DOI
  83. Rahnamoun, 2017, Mutant p53 shapes the enhancer landscape of cancer cells in response to chronic immune signaling, Nat. Commun., 8, 754, 10.1038/s41467-017-01117-y · DOI
  84. Ralff, 2018, TRAIL pathway targeting therapeutics, Expert Rev. Precis. Med. Drug Dev., 3, 197, 10.1080/23808993.2018.1476062 · DOI
  85. Ross, 2008, How the Smads regulate transcription, Int. J. Biochem. Cell Biol., 40, 383, 10.1016/j.biocel.2007.09.006 · DOI · Paper page
  86. Sag, 2019, The role of TRAIL/DRs in the modulation of immune cells and responses, Cancers (Basel), 11, 1469, 10.3390/cancers11101469 · DOI
  87. Sahin, 2021, Hyperprogression of a mismatch repair-deficient colon cancer in a humanized mouse model following administration of immune checkpoint inhibitor pembrolizumab, Oncotarget, 12, 2131, 10.18632/oncotarget.28086 · DOI
  88. Schmitz, 2000, Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides, Cancer Res., 60, 4845
  89. Schneider, 2010, Cross talk between stimulated NF-kappaB and the tumor suppressor p53, Oncogene, 29, 2795, 10.1038/onc.2010.46 · DOI · Paper page
  90. Shangary, 2008, Targeting the MDM2-p53 interaction for cancer therapy, Clin. Cancer Res., 14, 5318, 10.1158/1078-0432.Ccr-07-5136 · DOI · Paper page
  91. Shi, 2021, A different facet of p53 function: Regulation of immunity and inflammation during tumor development, Front. Cell Dev. Biol., 9, 762651, 10.3389/fcell.2021.762651 · DOI
  92. Shick, 1997, Decreased immunoglobulin deposition in tumors and increased immature B cells in p53-null mice, Cell Growth & Differ., 8, 121
  93. Smyth, 2003, Nature's TRAIL—on a path to cancer immunotherapy, Immunity, 18, 1, 10.1016/S1074-7613(02)00502-2 · DOI · Paper page
  94. Sobel, 1996, Cellular interactions in the lpr and gld models of systemic autoimmunity, Adv. Dent. Res., 10, 76, 10.1177/08959374960100011601 · doi:10.1177/08959374960100011601
  95. Swann, 2007, Immune surveillance of tumors, J. Clin. Invest., 117, 1137, 10.1172/jci31405 · DOI · Paper page
  96. Takahashi, 1994, Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand, Cell, 76, 969, 10.1016/0092-8674(94)90375-1 · DOI · Paper page
  97. Tang, 2021, Mutant p53 regulates Survivin to foster lung metastasis, Genes Dev., 35, 528, 10.1101/gad.340505.120 · DOI
  98. Tesei, 2021, TP53 drives abscopal effect by secretion of senescence-associated molecular signals in non-small cell lung cancer, J. Exp. Clin. Cancer Res., 40, 89, 10.1186/s13046-021-01883-0 · DOI
  99. Uddin, 2022, p53 missense mutant G242A subverts natural killer cells in sheltering mouse breast cancer cells against immune rejection, Exp. Cell Res., 417, 113210, 10.1016/j.yexcr.2022.113210 · DOI
  100. van der Burg, 2002, Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine, Clin. Cancer Res., 8, 1019
  101. Walton, 2016, CRISPR/Cas9-Mediated Trp53 and Brca2 knockout to generate improved murine models of ovarian high-grade serous carcinoma, Cancer Res., 76, 6118, 10.1158/0008-5472.CAN-16-1272 · DOI · Paper page
  102. Wang, 2013, p53 increases MHC class I expression by upregulating the endoplasmic reticulum aminopeptidase ERAP1, Nat. Commun., 4, 2359, 10.1038/ncomms3359 · DOI
  103. Wang, Toxicities associated with PD-1/PD-L1 blockade, Cancer J., 24, 36, 10.1097/ppo.0000000000000296 · DOI
  104. Wang, Regulation of PD-L1: Emerging routes for targeting tumor immune evasion, Front. Pharmacol., 9, 536, 10.3389/fphar.2018.00536 · DOI · Paper page
  105. Wellenstein, 2019, Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis, Nature, 572, 538, 10.1038/s41586-019-1450-6 · DOI · Paper page
  106. Wilkins-Port, 2009, TGF-beta1 + EGF-initiated invasive potential in transformed human keratinocytes is coupled to a plasmin/MMP-10/MMP-1-dependent collagen remodeling axis: Role for PAI-1, Cancer Res., 69, 4081, 10.1158/0008-5472.CAN-09-0043 · DOI
  107. Wormann, 2016, Loss of P53 function activates JAK2-STAT3 signaling to promote pancreatic tumor growth, stroma modification, and gemcitabine resistance in mice and is associated with patient survival, Gastroenterology, 151, 180, 10.1053/j.gastro.2016.03.010 · DOI · Paper page
  108. Wu, 1997, KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene, Nat. Genet., 17, 141, 10.1038/ng1097-141 · DOI · Paper page
  109. Yadollahi, 2021, Current understanding of cancer-intrinsic PD-L1: Regulation of expression and its protumoral activity, BMB Rep., 54, 12, 10.5483/BMBRep.2021.54.1.241 · DOI
  110. Yamada, 2017, Dual role of fas/FasL-mediated signal in peripheral immune tolerance, Front. Immunol., 8, 403, 10.3389/fimmu.2017.00403 · DOI · Paper page
  111. Yanai, 2007, Role of IFN regulatory factor 5 transcription factor in antiviral immunity and tumor suppression, Proc. Natl. Acad. Sci. U. S. A., 104, 3402, 10.1073/pnas.0611559104 · DOI · Paper page
  112. Yoon, 2009, PKR, a p53 target gene, plays a crucial role in the tumor-suppressor function of p53, Proc. Natl. Acad. Sci. U. S. A., 106, 7852, 10.1073/pnas.0812148106 · DOI
  113. Zhang, 2022, Advanced strategies for therapeutic targeting of wild-type and mutant p53 in cancer, Biomolecules, 12, 548, 10.3390/biom12040548 · DOI
  114. Zhang, 2023, Role of regulation of PD-1 and PD-L1 expression in sepsis, Front. Immunol., 14, 1029438, 10.3389/fimmu.2023.1029438 · DOI
  115. Zhou, 2019, Immunogenic cell death in cancer therapy: Present and emerging inducers, J. Cell Mol. Med., 23, 4854, 10.1111/jcmm.14356 · DOI · Paper page
  116. Zhou, 2021, Pharmacologic activation of p53 triggers viral mimicry response thereby abolishing tumor immune evasion and promoting antitumor immunity, Cancer Discov., 11, 3090, 10.1158/2159-8290.Cd-20-1741 · DOI · Paper page
  117. Zhu, 1999, p53 induces TAP1 and enhances the transport of MHC class I peptides, Oncogene, 18, 7740, 10.1038/sj.onc.1203235 · DOI

Cited by

See all 100

Metadata

Authors
Carlsen, L., Zhang, S., Tian, X., De La Cruz, A., George, A., Arnoff, T. E., & El-Deiry, W. S.
Venue
Frontiers in Molecular Biosciences
Publisher
Frontiers Media SA
Published
2023-08-01
Volume
10
ISSN
2296-889X
DOI
10.3389/fmolb.2023.1148389
Cited by
100
References
20
Licence
creativecommons.org/licenses/by/4.0/ (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The role of p53 in anti-tumor immunity and response to immunotherapy. https://app.cochat.ai/papers/10.3389/fmolb.2023.1148389
The paper
Carlsen, L., Zhang, S., Tian, X., De La Cruz, A., George, A., Arnoff, T. E., & El-Deiry, W. S. (2023). The role of p53 in anti-tumor immunity and response to immunotherapy. Frontiers in Molecular Biosciences. https://doi.org/10.3389/fmolb.2023.1148389

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.